Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.

UNLABELLED: (111)In-nuclear localization sequence-trastuzumab is a radioimmunotherapeutic agent consisting of trastuzumab modified with NLS peptides (CGYGPKKKRKVGG) and labeled with the Auger electron emitter (111)In. Our objectives were to evaluate the tumor growth-inhibitory properties and normal-...

Full description

Bibliographic Details
Main Authors:	Costantini, D, McLarty, K, Lee, H, Done, S, Vallis, K, Reilly, R
Format:	Journal article
Language:	English
Published:	2010

Similar Items

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
by: McLarty, K, et al.
Published: (2009)

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
by: McLarty, K, et al.
Published: (2009)

Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
by: Chen, P, et al.
Published: (2003)

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
by: Costantini, D, et al.
Published: (2008)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
by: Costantini, D, et al.
Published: (2010)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
by: Costantini, D, et al.
Published: (2007)

In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
by: Cornelissen, B, et al.
Published: (2009)

The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
by: Cornelissen, B, et al.
Published: (2008)

Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
by: Cornelissen, B, et al.
Published: (2008)

Biodistribution and nuclear import of 111In-labeled HIV-1 tat peptide immunoconjugates after intravenous or intratumoural injection in tumour-bearing mice
by: Cornelissen, B, et al.
Published: (2006)

Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells.
by: Cornelissen, B, et al.
Published: (2007)

Kinetics of internalization and nuclear import and efflux of 111In-and 123I-labeled HIV-1 tat-peptide immunoconjugates (IC's) in BT-474 human breast cancer cells
by: Cornelissen, B, et al.
Published: (2006)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
by: Mohd Nafi, SN
Published: (2014)

111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
by: Cornelissen, B, et al.
Published: (2009)

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts
by: Kumar, K, et al.
Published: (2013)

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.
by: Kumar, K, et al.
Published: (2013)

Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model.
by: Kramer-Marek, G, et al.
Published: (2012)

Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.
by: Nölting, S, et al.
Published: (2014)

Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer.
by: Gijsen, M, et al.
Published: (2010)

Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
by: Arshad, M, et al.
Published: (2024)

The anti-tumor effect of the auger electron-emitting radiopharmaceutical, In-111-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent.
by: Chen, P, et al.
Published: (2001)

The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
by: Cesca, M, et al.
Published: (2009)

Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.
by: Cohen-Jonathan, E, et al.
Published: (2000)

Assessment Of Antitumor Activity Of Standardized Polyalthia Longifolia Leaf Extract In Hela Cell Tumor Xenograft Mouse Model
by: Braganza, Cilwyn Shalitha
Published: (2022)

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
by: Iwata, Hiroji, et al.
Published: (2019)

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
by: Early Breast Cancer Trialists’ Collaborative group (EBCTCG)
Published: (2021)

Assessing the role of ADAM10 in Trastuzumab treatment and resistance
by: Feldinger, K
Published: (2012)

Trastuzumab-associated cardiac events in the Persephone trial
by: Earl, H, et al.
Published: (2016)

Adverse effects of being a "healthy carrier".
by: McLarty, E, et al.
Published: (1999)

Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
by: Hu, M, et al.
Published: (2007)

Antitumor and antioxidant effects of Clinacanthus nutans Lindau in 4T1 tumor-bearing mice
by: Nik Abd Rahman, Nik Mohd Afizan, et al.
Published: (2019)

Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.]
by: Hasbullah, Harissa H, et al.
Published: (2018)

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
by: Bailey, K, et al.
Published: (2007)

Business basics / [kaset]
by: 460268 Grant, David, et al.
Published: (1995)

In vivo characterization of [123I]-2-Iodo-L-Phenylalanine in growing R1M rabdomyosarcoma bearing athymic mice as a potential tumour tracer for SPECT
by: Kersemans, V, et al.
Published: (2004)

Possible Radiation Sensitisation by Trastuzumab Leading to Radiation-Induced Myelitis.
by: Law, AB, et al.
Published: (2009)

Healing response to various forms of human demineralized bone matrix in athymic rat cranial defects.
by: Chesmel, K, et al.
Published: (1998)

Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.
by: Wang, J, et al.
Published: (2003)

Antisense imaging of epidermal growth factor (EGF) induced p21(WAF-1/CIP-1) mRNA in MDA-MB-468 human breast cancer xenografts.
by: Wang, J, et al.
Published: (2002)

Biodistribution and pharmacokinetic studies of a porphyrin dimer photosensitizer (Oxdime) by fluorescence imaging and spectroscopy in mice bearing xenograft tumors
by: Khurana, M, et al.
Published: (2012)